Press Release

Press Release
RepliCel Signs Letter of Intention (Asset Purchase)
RepliCel announces a Letter of Intent for Asset Purchase AgreementVANCOUVER, BC, CANADA –March 18, 2024...
Press Release
Arbitration decision
RepliCel Life Sciences Announces Arbitration Decision VANCOUVER, BC – October 16, 2023 - RepliCel Life...
Press Release
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration ProceedingsVANCOUVER, BC, CANADA – September 13, 2023 –...
Press Release
David Kwok is appointed Chief Financial Officer
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is...
Press Release
RepliCel Adds an Additional Director, Jamie Mackay
 RepliCel Adds an Additional Director  RepliCel Life Sciences Strengthens Its Board of Directors as focus shifts...
Press Release
RepliCel Announces Closing of Non-brokered Private Placement
RepliCel Announces Closing of Non-brokered Private PlacementNot for distribution to U.S. Newswire Services or for...
Press Release
Replicel Announces Extension to Private Placement
VANCOUVER, BC – May 6, 2022 – Replicel Life Sciences Inc. (the “Company” or “Replicel”) announces...
Press Release
RepliCel Announces Non-brokered Private Placement
Not for distribution to U.S. Newswire Services or for dissemination in the United States.VANCOUVER, BC,...
Press Release,Product - RCI-02
RepliCel Announces Material Patent Milestones
New DermaPrecise™ patent application and patents granted for tendinopathy and skin rejuvenation technologies in key...
Press Release
RepliCel Terminates License Agreement with Shiseido
VANCOUVER, BC, CANADA – 21 December 2021 – RepliCel Life Sciences Inc. (OTCPK: REPCF) (TSXV: RP) (FRA:P6P2)...
Press Release
RepliCel Closed Final Tranche of Strategic Investment Commitment
VANCOUVER, BC, CANADA – 21 December 2021 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) (“RepliCel”...
Press Release
RepliCel Ships DermaPreciseTM Injector Prototypes and Consumables to Independent Laboratory for Clinical Simulation Testing
Independent dermatology research experts at Monasterium Laboratory GmbH will test, analyze and validate various injection...
Press Release,Product - RCI-02
RepliCel’s Clinical Advisory Team Delivers Skin Rejuvenation Clinical Study Synopsis to its Japanese Regulatory and Clinical Study Management Team
RepliCel’s CRO and regulatory advisors now begin preparing Japanese-language documentation to support study clearanceVANCOUVER, BC,...
Press Release
RepliCel Announces DermaPrecise Trademark for Dermal Injector Product Line
Trademark registrations kickoff pre-commercial planningVANCOUVER, BC, CANADA – 28 October 2021 – RepliCel Life Sciences...
Press Release,Product - RCI-02
RepliCel Announces Dermal Injector Update
Testing progresses to next-phase; results lead to some component upgrades to ensure optimal performance, quality...
Press Release
RepliCel Files Notice of Arbitration against Shiseido Company to Resolve its License Agreement Dispute Regarding its Androgenetic Alopecia Cell Therapy
After several unsuccessful attempts to settle the dispute, RepliCel has filed an arbitration claim seeking...
Press Release
RepliCel Life Sciences Appoints One of Japan’s Foremost Regenerative Medicine Industry Business Leaders as Strategic Advisor
Kunihiko Suzuki, one of the leading pioneers in Japan’s emerging regenerative medicine industry, commits to...
Press Release
RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents
Canadian granting agency MITACS commits to three years of funding for the project’s second stage...
Press Release
RepliCel Applies for Manufacturing Approval for its Collagen and Tissue Regeneration Cell Therapies
Clinical development of RepliCel’s skin rejuvenation and tendon regeneration injectables continues to meet milestones on...
Press Release
RepliCel Adds Independent Director
Board of Directors Strengthens Its Independence Oversight and Updates its Stock Options VANCOUVER, BC – June...

DISCLAIMER:
The information in these press releases is historical in nature, has not been updated, and is current only to the date indicated in the particular press release. This information may no longer be accurate and therefore you should not rely on the information contained in these press releases. To the extent permitted by law, RepliCel Life Sciences Inc. and its employees, agents and consultants exclude all liability for any loss or damage arising from the use of, or reliance on, any such information, whether or not caused by any negligent act or omission.

THIRD PARTY CONTENT
Please note that any opinion, estimates or forecasts made by the authors of these statements are theirs alone and do not represent opinions, forecasts or predictions of RepliCel Life Sciences Inc. or its management. RepliCel Life Sciences Inc. does not, by its reference or distribution of these links imply its endorsement of, or concurrence with, such information, conclusions or recommendations.